Biowatchdog, Do you think this is just Management being fastidious to ask for the June extension or is it possible the LoQ are complicated enough that they feel that they need all the time they can get? Theoretically, getting that *early* extension is sort of the only way Management could also accelerate the review process too, though, right?
A PR from headquarters, upgrade from analyst or even a *note* from Insti would be great. Either way, excellent news from the Poster Presentation!
A buyout doesn't allow Management/BOD a perpetual gravy train either. Lewis has plenty of money and was a Hedge Fund guy for years so who knows what his long term goals really are? He does seem passionate about CF/NTM and making positive advances, though. But raising money to buy more IP right now seems insulting to common shareholders unless it's an immediately accretive asset. For heaven's sake, get Arikace on the market already! How many years since the Rat debacle....five?! Sheesh...
Bio-tech is hands-down the hottest sector in the market right now and seemingly every BIOTECH has a B/O rumor attached to it. But more importantly, Mr. Lewis said that WE would probably be buying another company before Y/E so this *Buy Out* rumor could just be $$$ for those that would be front-running the potential deal. Cookie-cutter Wall St. stuff. Having said this, you can't help but enjoy the increased valuation whatever the case.
Genuine or not, I'm surprised he doesn't have Shire on that suitor list. Maybe they've already spent their allocated acquisition money but they should/would be in on a potential Insmed B/O, in my opinion.
Yeah, good to hear again but many, many years away. Everything is very slow going now...except for cash burn! These guys need to pull-off a Partnership while things are moving in BP/Biotech! What ever happened to Japan?!
I wonder if presently in Europe or if we do eventually get an FDA Approval for either CF or NTM, if this will validate to the point of allowing us/them to bypass full Phase Clinical Trials for other Liposomal attached Medications?
Yep. Looks like an open market buy as opposed to Options Exercised.
Real nice. Undeniably positive event...and dare I say, bullish?
Will be even better if we see a slew of other open market buys as we are now, obviously, in the period for Insiders to buy, etc.
Practically every *Analyst* covering (except Webush, who actually called this near perfectly. Coincidence?) is getting a piece of this latest dilution. Oh, but wait! This Offering means that these *Banks* believe in Insmed, just like we little ole' common holders! Oh, how warm and fuzzy! They would never go long AND short and reiterate Price Targets just because they know WELL in advance what's coming! NOPE. NEVER!
Hopefully, our Money Raising, Hedge Fund CEO can actually secure a Partnership.....or who knows....maybe there is another Slam Dunk Transave type company out there that every major Pharma has ignored that just needs a little cash.
Holding long is undeniably a suckers bet when you're on the outside like we Retail Holders.
Congrats to you traders out there for ignoring the spoon-fed *messages.* Well done.
All good points and it certainly would be a relief to see partnership agreements signed soon. Drechsler's comment at yesterday's CC stating that the company would be *opportunistic raising capital...*, our CEO's close relationships w/ banks, at least 20 million needed for new trials, a monthly Burn Rate of 5 million(?) and pretty much no substantial news for the rest of the year could mean dilution is coming, though.
Yep, we'll see.
Today was a disappointment. No other way to spin it. Mr. Lewis is soooooooo excited that we now finally have regulatory clarity and have a partner in the FDA?!? Hmmmm, our partner (FDA) just sent us back to the 20 yard line. We are now YEARS away in the US. Period. I was fooled by the Break Through Therapy Designation because it obviously turned out to be meaningless. Oh well. A Banker as CEO ain't all bad if you're on the *inside*.
It all comes down to Europe now. For some of us, anyway.
LOL. Good one. (ahem)
He got his clients out in the $19. range and he was more or less right about the NTM trial. So, tell me this: are we now closer to Webush's $7.00 OR Piper's $51. ?!?
You KNOW Piper's prolly front-running any offering...shorting for good measure too boot.
Silly me for buying and holding and not trading the stock.
Yep, and those in-the-know will have hedged, shorted and yes, even longed their way to serious enrichment.
Gonna take quite the news releases to get this back to $20. And IF it does, some of us will certainly be lamenting/wondering that it should/could have been $30. or more if not for Gupta's trial design and now Lewis hammering us and gifting his Wall St. colleagues.
Wade/Webush were right, all along.
Oh, WHEW! They'll be no dilution to current shareholders or any proposed stock sales. Just a little Friday afternoon desk-clearing. Nothing to see here. Sweet! (exhale)
It means that Management (Mr. Lewis IS a banker, first and foremost) has shamefully waited until after the close on a Friday to let us know that we are to be diluted. (We KNOW Webush didn't get the deal, don't we!?) May also signal that an NTM PH III is coming. We'll just see how many shares and what Lewis has priced the offering at.
So much for the *Asian Partnership*, eh?
Bit of a Perfect Storm with the *failed* Primary Endpoint of the NTM Trial coinciding with the Biotech Correction. Dilution is always a concern with Bio's especially depending upon what exactly the FDA says with regards to the NTM situations and increased monthly burn with new hires, infrastructure, etc. as well. But you can't help but think that there will be significant off-label prescriptions from the Euro/Canadian CF indication, though, no matter. Mr. Lewis hasn't said much about off-label Rx because, well, he's not supposed too. Theoretically, even with a PH III NTM trial underway (IF needed), patients outside of a trial might be prescribed Arykace, elsewhere, right?
Lewis did announce at the Leerink C/C that he would have an analysis of the data by the Lead Investigators of the study on the NTM Conference Call so I would guess it's just the way he likes do things. Would have to imagine that IF the data isn't a homerun, there is more than likely at least a sub-set of patients that responded well, etc. With this Biotech *correction* underway on Wall Street, if the data is indeed decent, there could be a lot of investors flocking to Insmed tomorrow.